Media Articles Related to Fareston (Toremifene)
Scripps Florida scientists predict cell changes that affect breast cancer growth, opening door to more effective therapies
Source: Breast Cancer News From Medical News Today [2016.04.29]
Designing effective new drugs, especially drugs to fight cancer, demands that you know as much as you can about the molecular workings of cancer growth.
A long-noncoding RNA regulates repair of DNA breaks in triple-negative breast cancer cells
Source: Breast Cancer News From Medical News Today [2016.04.29]
Findings give 'new insight' into biology of tough-to-treat breast cancer.The discovery of long non-coding RNA (lncRNA) has dramatically changed the understanding of the biology of diseases such...
Metastectomies: Local Approaches to Breast Cancer Metastases
Source: Medscape General Surgery Headlines [2016.04.28]
In expert panel reported on the increasing the use of radiation therapy and surgery to control low-volume metastatic disease in patients with breast cancer, as part of the 2016 EBCC in Amsterdam.
Big Data vs Breast Cancer Trials Raises Big Issues
Source: Medscape Hematology-Oncology Headlines [2016.04.27]
Using big data in place of clinical trials to answer clinical questions may sound progressive. But judging from the results of a recent study, it raises big issues, says Dr Kathy Miller.
Vanderbilt-Ingram Cancer Center-led study finds explanation for some treatment-resistant breast cancers
Source: Breast Cancer News From Medical News Today [2016.04.27]
A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study.
Published Studies Related to Fareston (Toremifene)
Prostate cancer diagnosis among men with isolated high-grade intraepithelial
neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral
high-grade prostatic intraepithelial neoplasia (HGPIN) on biopsy... CONCLUSION: Although toremifene 20 mg did not lower the PCa detection rate, men
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy
for prostate cancer. 
therapy during a 2-year period... CONCLUSIONS: Toremifene significantly decreased the incidence of new vertebral
Toremifene decreases vertebral fractures in men younger than 80 years receiving
androgen deprivation therapy for prostate cancer. 
men younger than 80 years... CONCLUSIONS: Toremifene significantly decreased new vertebral fractures in men
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. [2010.10]
PURPOSE: Androgen deprivation therapy is associated with fracture risk in men with prostate cancer. We assessed the effects of toremifene, a selective estrogen receptor modulator, on fracture incidence in men receiving androgen deprivation therapy during a 2-year period... CONCLUSIONS: Toremifene significantly decreased the incidence of new vertebral fractures in men receiving androgen deprivation therapy for prostate cancer. It also significantly improved bone mineral density, bone turnover markers and serum lipid profiles. Copyright (c) 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial. [2010.07]
OBJECTIVE: Toremifene and tamoxifen have been used for adjuvant therapy in post-menopausal patients with breast cancer in Japan. Dyslipidemias are common in post-menopausal women. However, limited data are available on the effects of these agents on lipid profiles in Japanese patients. The Japan Toremifene Cooperative Study Group has been conducting a Phase III randomized trial of post-menopausal patients with breast cancer. One of its secondary endpoints is to confirm the effects of these agents on serum lipid profiles... CONCLUSIONS: Distinct differences between two selective estrogen receptor modulators on lipids were observed. Toremifene improved lipid profiles, particularly as an enhancer of high-density lipoprotein cholesterol. To a large extent, tamoxifen improved low-density lipoprotein cholesterol levels. The impact of these improved lipid profiles on the risk of cardiovascular diseases needs further confirmation.
Clinical Trials Related to Fareston (Toremifene)
Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer [Recruiting]
To compare the safety of toremifene and tamoxifen therapy in premenopausal patients with
operable breast cancer by monitoring gynecological abnormality,blood lipid level,hepatic
abnormality,estrogen level and perimenopausal symptoms.
Changes in Breast 3D Ultrasound Measurements Using Toremifene [Completed]
The Effect of Toremifene Treatment to the Magnetic Resonance Imaging (MRI) Findings in Premenstrual Mastalgia [Completed]
The purpose of this study is to determine the effect of toremifene treatment to the MRI
findings of the breast in women suffering from premenstrual mastalgia.
Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer [Recruiting]
This study evaluates the addition melatonin and metformin to toremifene in the treatment of
locally advanced breast cancer. Third of patients will receive toremifene, other third will
receive combination of melatonin and toremifene and other patients will receive combination
of metformin and toremifene.
Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer [Terminated]
Protocol 777-CLP-32 is the treatment and survival continuation protocol of Biomed
777-CLP-29, and will continue to compare combined hormonal therapy using the experimental
aromatase inhibitor (AI) atamestane combined with the FDA-approved anti-estrogen toremifene
(Fareston«), to the single agent FDA-approved aromatase inhibitor letrozole (Femara«) for
the treatment of advanced breast cancer. The purpose of this study is to determine whether
maximal estrogen suppression achieved via the combination of atamestane, plus toremifene
(Fareston«), is more effective than letrozole (Femara┬«) in delaying the growth of breast
Reports of Suspected Fareston (Toremifene) Side Effects
Hepatic Function Abnormal (4),
White Blood Cell Count Decreased (4),
Interstitial Lung Disease (3),
Hepatitis Acute (2),
Condition Aggravated (2),
Respiratory Failure (2),
Neoplasm Progression (1),
Osteomyelitis (1), more >>